



Correction

Correction: Awad et al. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. *Pharmaceuticals* 2022, 15, 1068

Hoda Awad ¹, Basmala Hassan ¹, Sara Dweek ¹, Yasmeen Aboelata ¹, Mutasem Rawas-Qalaji ^{1,2} and Iman Saad Ahmed ^{1,2,*}

¹ Department of Pharmaceutics & Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; u19104592@sharjah.ac.ae (H.A.); u17100019@sharjah.ac.ae (B.H.); u17103078@sharjah.ac.ae (S.D.); u17102409@sharjah.ac.ae (Y.A.); mqalaji@sharjah.ac.ae (M.R.-Q.)

² Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah 27272, United Arab Emirates

* Correspondence: iahmed@sharjah.ac.ae; Tel.: +971-65057403

Text Correction

The following paragraph, “Coinciding but insignificant findings with regards to the time to negative PCR were established by Pott-Junior et al. in a randomized open-label study conducted at Federal University of São Carlos, Brazil, in a group of 32 mild COVID-19 patients who received standard of care (SOC) alone, or SOC and oral IVM (3 different groups received the following doses: 100 µg/kg, 200 µg/kg and 400 µg/kg). The study did not report any serious adverse events in the SOC with IVM group. Patients receiving IVM required a shorter time to obtain two consecutive negative PCR result in a dose-dependent manner [52]”, should be ignored since the manuscript was retracted and is no longer part of the scientific record due to a lack of sufficient detail for some of the methods and approaches in the experimental design [1].

A correction has been made to delete this paragraph and the reference included in it. Additionally, the related content in Table 3 has been deleted, and all the other reference numbers have been reordered accordingly.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication [2] has also been updated.

References

1. Pott-Junior, H.; Paoliello, M.M.B.; de Queiroz Constantino Miguel, A.; da Cunha, A.F.; de Melo Freire, C.C.; Neves, F.F.; da Silva de Avó, L.R.; Roscani, M.G.; De Sousa dos Santos, S.; Chach', S.G.F. Retraction notice to “Use of ivermectin in the treatment of Covid-19: A pilot trial” [toxicol. rep. 8 (2021) 505–510]. *Toxicol. Rep.* **2022**, *9*, 1023. [[CrossRef](#)] [[PubMed](#)]
2. Awad, H.; Hassan, B.; Dweek, S.; Aboelata, Y.; Rawas-Qalaji, M.; Ahmed, I.S. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. *Pharmaceuticals* **2022**, *15*, 1068. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.



Citation: Awad, H.; Hassan, B.; Dweek, S.; Aboelata, Y.; Rawas-Qalaji, M.; Ahmed, I.S. Correction: Awad et al. Repurposing Potential of the Antiparasitic Agent Ivermectin for the Treatment and/or Prophylaxis of COVID-19. *Pharmaceuticals* **2022**, *15*, 1068. *Pharmaceuticals* **2024**, *17*, 1100. <https://doi.org/10.3390/ph17081100>

Received: 9 May 2024

Accepted: 14 May 2024

Published: 22 August 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).